By Fineline Cube 
Shanghai-based Jumpcan Pharmaceutical (SHA: 600566) announced that its independently developed Class 1 innovative drug, Jike Shu (generic name: Marsetlovir Tablets), has received marketing approval from the National Medical Products Administration (NMPA). The drug is indicated for the treatment of uncomplicated influenza A and B in previously healthy adults. It represents the first new-generation influenza virus RNA polymerase PA inhibitor with global independent intellectual property rights developed in China. Notably, the entire treatment course requires only a single oral dose.
Mechanism of Action
Jike Shu exerts its antiviral effects by specifically inhibiting the transcription of viral mRNA, thereby directly intervening in the core process of viral genome replication. This targeted mechanism enables the drug to effectively combat influenza viruses.
Clinical Profile
Clinical trials have demonstrated that Jike Shu possesses long-lasting antiviral activity. With a long half-life and rapid onset of action, the drug can reduce fever within one day and alleviate all influenza symptoms within approximately 39.4 hours. Additionally, it has shown good safety and a low risk of drug interactions.
Clinical Trials and Research
The Phase II/III clinical trials of Jike Shu were led by Professor Zhang Wenhong. The results have been published in the journal Clinical Microbiology and Infection. The clinical research was based entirely on data from the Chinese population, making it particularly suitable for the physiological characteristics of the Chinese people. Jike Shu was independently developed by Zenshine Pharmaceuticals, and Jumpcan acquired the exclusive promotion rights in Mainland China in August 2023.-Fineline Info & Tech